GlaxoSmithKline and Vir Biotechnology's monoclonal antibody drug Sotrovimab has received emergency use authorization from the FDA for the treatment of patients ages 12 and older with mild to moderate COVID-19. The drug should not be used for cases of COVID-19 that require hospitalization or oxygen therapy, the FDA said.
GSK, Vir's COVID-19 antibody drug gets EUA from FDA
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.